• Unresectable hepatocellular carcinoma:
    • PO 400mg BD
  • Advanced renal cell carcinoma:
    • PO 400mg BD
  • Refractory differentiated thyroid carcinoma:
    • PO 400mg BD
    • For patients with locally recurrent or metastatic, progressive disease and who are radioactive iodine-refractory

Tablet: 200mg

To be given at least 1 hour before or 2 hours after food

Tyrosine kinase inhibitor anticancer

It inhibits multiple tyrosine kinases including VEGF and BRAF, resulting in decreased angiogenesis, tumor growth and cancer progression

  • Thrombocytopenia
  • Anemia
  • Diarrhea
  • Rash/desquamation
  • Fatigue
  • Abdominal pain
  • Hand-foot skin reaction
  • Weight loss
  • Anorexia
  • Alopecia
  • Nausea
  • Lymphopenia
  • Neutropenia
  • Hemorrhage
  • Hypertension
  • Vomiting
  • Constipation
  • Neuropathy
  • Dry skin
  • Headache
  • Joint pain
  • Squamous cell lung cancer (combo with carboplatin and paclitaxel)
  • Squamous cell lung cancer (combo with cisplatin and gemcitabine)
  • Breastfeeding during treatment and for 2 weeks after discontinuation
  • GI perforation
  • Uncorrected electrolyte abnormalities
  • Congenital long QT syndrome
  • Unhealed surgical wound
  • Major surgery within prior 2 weeks
  • At least 10 days before an elective surgery
  • Dronedarone
  • Lefamulin
  • Pimozide
  • Saquinavir
  • Thioridazine
  • Ziprasidone

                          Drug Status

Availability Prescription only
Pregnancy Category D
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Nexavar 200mg Tablet 60’s, 112’s Bayer Schering Bayer Schering